10-K: Retractable Technologies Reports Weak 2024 Results Amid Tariff Headwinds and Internal Control Weaknesses

Retractable Technologies' 2024 results were negatively impacted by tariffs on Chinese imports, leading to a gross loss and concerns about internal control over financial reporting.

Summary

• Retractable Technologies, Inc. reported its Form 10-K for the fiscal year ended December 31, 2024.
• The company manufactures and markets safety medical products, primarily syringes.
• Revenues materially increased in 2020-2021 due to COVID-19 vaccination demand but decreased as sales to the U.S. government wound down in early 2022.
• International vaccination demand positively impacted sales throughout 2022 and the first quarter of 2023.
• In September 2024, a new 100% tariff on syringes and needles imported from China became effective, impacting financial results.
• Tariffs on Chinese imports were increased by an aggregate total of 20% effective February 4th and March 4th of 2025.
• Approximately $1.6 million was spent on tariff expenses from September to December 2024 due to the 100% tariff.
• From January 1 to March 21, 2025, approximately $951,000 was spent on tariff expenses.
• The company is shifting a larger portion of manufacturing to its domestic facility to lessen the financial impact of tariffs.
• Adaptations to equipment will allow domestic manufacturing of 0.5 mL syringes, expected to be available in commercial quantities in the second half of 2025.
• Syringe sales were 68.5% of revenues in 2024, 78.3% in 2023, and 91.5% in 2022.
• EasyPoint products accounted for 27.1% of sales in 2024, 16.6% in 2023, and 5.0% in 2022.
• The company is developing additional safety products, but they are not expected to be commercially available in 2025.
• International sales were closer to 10% of total sales for the remainder of 2023 and for 2024.
• As of March 10, 2025, the company had 227 employees.
• The aggregate market value of the common equity held by non-affiliates as of June 30, 2024, was $14.6 million.
• As of March 10, 2025, there were 29,937,159 shares of Common Stock outstanding, excluding treasury shares.
• The company's stock price reached a low of $0.57 per share in 2024 despite a strong balance sheet.
• The company's headquarters are located in Little Elm, Texas, on 35 acres, which it owns.
• The company's internal control over financial reporting was not effective as of December 31, 2024.
• The company did not maintain the risk assessment and control activities components of the COSO framework.
• The company did not design and maintain effective controls to timely document and evaluate revenue contract terms and the related revenue recognition accounting conclusions when entering into significant revenue contracts.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to the reported gross loss, increased net loss, ineffective internal controls, and the impact of tariffs. While the company is taking steps to mitigate these issues, the overall tone is concerning from an investment perspective.

Positives

• The company is actively working to mitigate the impact of tariffs by shifting manufacturing to its domestic facility.
• Adaptations to equipment will allow domestic manufacturing of 0.5 mL syringes, reducing reliance on imports.
• The company has significant additional domestic production capacity for some products due to past investments.
• The company is committed to attracting and retaining talent through market-competitive wages and benefits.
• The company is enhancing its review and analysis of contractual modifications with customers to improve financial reporting.

Negatives

• The company reported a gross loss for 2024 due to the impact of tariffs and decreased revenue.
• The company's internal control over financial reporting was not effective as of December 31, 2024.
• The company did not maintain the risk assessment and control activities components of the COSO framework.
• The company did not design and maintain effective controls to timely document and evaluate revenue contract terms and the related revenue recognition accounting conclusions when entering into significant revenue contracts.
• The company's stock price reached a low of $0.57 per share in 2024 despite a strong balance sheet.

Risks

• Recent tariffs on products imported from China are expected to have a material negative impact on the company's results of operations and financial position.
• The company is reliant on Chinese manufacturers to provide products it is not able to manufacture domestically.
• The company is challenged by uncertainties in obtaining and enforcing intellectual property rights.
• The company is vulnerable to the development of superior competing products and to changes in technology.
• The company is controlled by one shareholder, Thomas J. Shaw, who has significant influence over the company's operations and financial affairs.
• Supply chain disruptions could negatively impact the company's profitability.
• Inflationary price pressures and uncertain availability of commodities, raw materials, utilities, labor or other inputs could negatively impact the company's profitability.
• Vaccine hesitancy could impact demand for the company's products.
• The company faces inherent product liability risks.
• The company's business may be affected by changes in the health care regulatory environment.
• The company may experience losses in its investment account.
• Health crises could have an adverse effect on the company's business.
• Disruption of critical information systems or material breaches in the security of the company's systems could harm the company's business, customer relations, and financial condition.
• Illegal distribution and sale by third parties of counterfeit versions of the company's products could have a negative impact.

Future Outlook

The company expects commercial quantities of domestically manufactured 0.5 mL syringes to be available for sale in the second half of 2025. The company believes it will have adequate means to meet its short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements. The company expects to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of its domestic equipment to align to its plan to produce more units at its U.S. facility.

Management Comments

• Management intends to enhance our review and analysis of contractual modifications with our customers, utilizing senior members of our accounting team, including the CFO, to identify and properly classify revenue transactions and their impact on our financial statements.
• Management believes that such enhancements to our review and analysis procedures will prevent errors from occurring, or that potential errors will be discovered and remediated in a timely manner.

Industry Context

The medical device industry is highly competitive, with larger companies having greater resources. Tariffs and global events can significantly impact supply chains and profitability. Safety features in medical devices are increasingly important.

Comparison to Industry Standards

• Becton, Dickinson and Company (BD) spun off a portion of its syringe, needle, and injection product division as Embecta Corp. (Embecta) in April 2022.
• Embecta has 2,100 employees, as compared to Retractable Technologies' 227 employees, indicating a significant difference in scale.
• Embecta licenses existing BD intellectual property and has continued to use the BD branding on its products and is provided with certain other services by BD.
• Embecta's 2024 annual report indicated that the company had 2,100 employees, as compared to our workforce of 227 employees.
• With resources greatly in excess of our own, we expect Embecta will be a formidable competitor.

Legal Proceedings

• The company is involved in a lawsuit against Locke Lord, LLP and Roy Hardin, with a new trial date set for June 2, 2025.
• The company withdrew its complaint in the United States Court of International Trade against the United States of America, the Office of the United States Trade Representative, Trade Representative Katherine Tai, U.S. Customs & Border Protection, and U.S. Customs & Border Protection Acting Commissioner Troy Miller, and the case was dismissed effective January 8, 2025.

Related Party Transactions

• The company has a license agreement with its Chief Executive Officer, Thomas J. Shaw.
• On December 26, 2022, the company approved the repurchase of three million shares of stock at $1.60 per share from BML Investment Partners, L.P., a 10% stockholder at the time of the transaction.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the impact of tariffs on profitability.
• Employees may be affected by changes in manufacturing operations and potential cost-cutting measures.
• Customers may experience changes in product availability and pricing due to tariffs and supply chain adjustments.
• Suppliers may be affected by changes in the company's sourcing strategies.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company intends to enhance its review and analysis of contractual modifications with its customers, utilizing senior members of our accounting team, including the CFO, to identify and properly classify revenue transactions and their impact on our financial statements.
• The company expects to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of its domestic equipment to align to its plan to produce more units at its U.S. facility.
• A new trial date has been set for June 2, 2025 for the lawsuit filed in the 44th District Court of Dallas County, Texas (No. DC-19-17946) against Locke Lord, LLP and Roy Hardin.

Key Dates

Keywords

tariffs, syringes, manufacturing, medical devices, internal control, revenue recognition, China, vaccination, EasyPoint, VanishPoint